Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $16.8 million.

  • Silence Therapeutics' Total Current Liabilities rose 179.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.4 million, marking a year-over-year increase of 179.09%. This contributed to the annual value of $16.8 million for FY2024, which is 24.69% down from last year.
  • Silence Therapeutics' Total Current Liabilities amounted to $16.8 million in FY2024, which was down 24.69% from $22.3 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Total Current Liabilities peaked at $32.8 million during FY2020, and registered a low of $16.8 million during FY2024.
  • Over the past 3 years, Silence Therapeutics' median Total Current Liabilities value was $22.3 million (recorded in 2023), while the average stood at $22.1 million.
  • In the last 5 years, Silence Therapeutics' Total Current Liabilities skyrocketed by 166.46% in 2020 and then tumbled by 36.46% in 2021.
  • MRY analysis of 5 years shows Silence Therapeutics' Total Current Liabilities stood at $32.8 million in 2020, then tumbled by 36.46% to $20.9 million in 2021, then soared by 30.14% to $27.2 million in 2022, then decreased by 17.75% to $22.3 million in 2023, then dropped by 24.69% to $16.8 million in 2024.
  • Its Total Current Liabilities was $16.8 million in FY2024, compared to $22.3 million in FY2023 and $27.2 million in FY2022.